AU2018312328B2 - Carbamoyl phenylalaninol analogs and uses thereof - Google Patents

Carbamoyl phenylalaninol analogs and uses thereof Download PDF

Info

Publication number
AU2018312328B2
AU2018312328B2 AU2018312328A AU2018312328A AU2018312328B2 AU 2018312328 B2 AU2018312328 B2 AU 2018312328B2 AU 2018312328 A AU2018312328 A AU 2018312328A AU 2018312328 A AU2018312328 A AU 2018312328A AU 2018312328 B2 AU2018312328 B2 AU 2018312328B2
Authority
AU
Australia
Prior art keywords
compound
disorder
subject
pharmaceutically acceptable
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018312328A
Other languages
English (en)
Other versions
AU2018312328A1 (en
Inventor
Fionn Hurley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Ireland Ltd
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of AU2018312328A1 publication Critical patent/AU2018312328A1/en
Application granted granted Critical
Publication of AU2018312328B2 publication Critical patent/AU2018312328B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/18Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02Monothiocarbamic acids; Derivatives thereof
    • C07C333/04Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018312328A 2017-07-31 2018-07-31 Carbamoyl phenylalaninol analogs and uses thereof Active AU2018312328B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539088P 2017-07-31 2017-07-31
US62/539,088 2017-07-31
PCT/US2018/044465 WO2019027941A1 (en) 2017-07-31 2018-07-31 CARBAMOYL PHENYLALANINOL ANALOGUES AND USES THEREOF

Publications (2)

Publication Number Publication Date
AU2018312328A1 AU2018312328A1 (en) 2020-03-19
AU2018312328B2 true AU2018312328B2 (en) 2022-12-15

Family

ID=65233074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018312328A Active AU2018312328B2 (en) 2017-07-31 2018-07-31 Carbamoyl phenylalaninol analogs and uses thereof

Country Status (12)

Country Link
US (3) US11413264B2 (enExample)
EP (1) EP3661911A4 (enExample)
JP (2) JP7366002B2 (enExample)
KR (1) KR102643275B1 (enExample)
CN (1) CN111094238B (enExample)
AU (1) AU2018312328B2 (enExample)
CA (1) CA3071779A1 (enExample)
MX (2) MX2020001146A (enExample)
RU (1) RU2020108634A (enExample)
SA (1) SA520411187B1 (enExample)
SG (1) SG11202000817SA (enExample)
WO (1) WO2019027941A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
RU2020108634A (ru) * 2017-07-31 2021-09-02 Джаз Фармасьютикалз Айрлэнд Лимитед Аналоги карбамоилфенилаланинола и способы их применения
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP4531833A2 (en) * 2022-06-03 2025-04-09 Axsome Therapeutics Carbamoyl phenylalaninol compounds as taar1 agonists

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017636A1 (en) * 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US5935997A (en) * 1998-01-13 1999-08-10 Yukong Limited O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically useful salts and process for preparing the same
WO2000044770A1 (en) * 1999-01-28 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Substituted phenethylamine derivatives
WO2000046191A1 (en) * 1999-02-05 2000-08-10 Sk Corporation O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically acceptable salts and process for preparing the same
WO2000064865A1 (en) * 1999-04-23 2000-11-02 Solvay Pharmaceuticals B.V. Monomers and oligourea peptidomimetics and process for the prepa ration thereof
WO2002100804A2 (en) * 2001-06-08 2002-12-19 Avantium International, B.V. Novel use of sulfamic acids as resolving agent.
CN101823987A (zh) * 2009-03-06 2010-09-08 中国科学院上海药物研究所 一类新的dpp-ⅳ抑制剂及其制备方法和用途
CN102249833A (zh) * 2011-05-27 2011-11-23 中国科学院化学研究所 一种制备手性γ-氨基酸及其衍生物的方法
WO2017007695A1 (en) * 2015-07-09 2017-01-12 The Regents Of The University Of California Mu opioid receptor modulators

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2604434B1 (fr) * 1986-09-29 1989-05-19 Inst Nat Sante Rech Med Derives d'amino-2 ethanethiol, leur preparation et leur application en therapeutique
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
CA2240060C (en) * 1996-10-10 2007-07-17 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
JP4374441B2 (ja) 1998-12-23 2009-12-02 ジェイピーアイ コマーシャル,リミティド ライアビリティ カンパニー 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
KR100576372B1 (ko) * 2001-08-03 2006-05-03 에스케이 주식회사 O-티오카바모일-아미노알카놀 화합물, 이의 약학적 허용염 및 제조방법
ITFI20030113A1 (it) * 2003-04-24 2004-10-25 Menarini Ricerche Spa Composti lineari nk-2 antagonisti con caratteristiche basiche e formulazioni che li contengono.
WO2006050037A1 (en) 2004-10-28 2006-05-11 Sk Corporation Adjunctive therapy for depression
PL1890684T3 (pl) * 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
ATE459393T1 (de) 2005-06-22 2010-03-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
RU2557533C2 (ru) 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
BR112015022197B1 (pt) 2013-03-13 2022-06-07 Sk Biopharmaceuticals Co., Ltd. Uso de um composto para o tratamento de cataplexia
US20150018414A1 (en) 2013-07-12 2015-01-15 Jazz Pharmaceuticals International lll Limited Promotion of Smoking Cessation
CN105873576B (zh) 2013-07-18 2019-07-19 爵士制药国际Iii有限公司 治疗肥胖
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
SG11201903076QA (en) 2016-10-06 2019-05-30 Jazz Pharmaceuticals International Iii Ltd Carbamoyl phenylalaninol compounds and uses therof
RU2020108634A (ru) 2017-07-31 2021-09-02 Джаз Фармасьютикалз Айрлэнд Лимитед Аналоги карбамоилфенилаланинола и способы их применения

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017636A1 (en) * 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US5935997A (en) * 1998-01-13 1999-08-10 Yukong Limited O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically useful salts and process for preparing the same
WO2000044770A1 (en) * 1999-01-28 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Substituted phenethylamine derivatives
WO2000046191A1 (en) * 1999-02-05 2000-08-10 Sk Corporation O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically acceptable salts and process for preparing the same
WO2000064865A1 (en) * 1999-04-23 2000-11-02 Solvay Pharmaceuticals B.V. Monomers and oligourea peptidomimetics and process for the prepa ration thereof
WO2002100804A2 (en) * 2001-06-08 2002-12-19 Avantium International, B.V. Novel use of sulfamic acids as resolving agent.
CN101823987A (zh) * 2009-03-06 2010-09-08 中国科学院上海药物研究所 一类新的dpp-ⅳ抑制剂及其制备方法和用途
CN102249833A (zh) * 2011-05-27 2011-11-23 中国科学院化学研究所 一种制备手性γ-氨基酸及其衍生物的方法
WO2017007695A1 (en) * 2015-07-09 2017-01-12 The Regents Of The University Of California Mu opioid receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GROS C. et al., "Potent Inhibition of Cerebral Aminopeptidases by Carbaphetiol, a Parenterally Active compound", Neuropeptides, (1988-10-01), vol. 12, no. 3, pages 111 - 118 *

Also Published As

Publication number Publication date
US20210093603A1 (en) 2021-04-01
CN111094238A (zh) 2020-05-01
US11413264B2 (en) 2022-08-16
JP2023100758A (ja) 2023-07-19
WO2019027941A1 (en) 2019-02-07
RU2020108634A (ru) 2021-09-02
SG11202000817SA (en) 2020-02-27
US20220401401A1 (en) 2022-12-22
NZ762140A (en) 2024-11-29
MX2020001146A (es) 2020-08-20
EP3661911A4 (en) 2021-04-14
CA3071779A1 (en) 2019-02-07
MX2023005484A (es) 2023-05-18
AU2018312328A1 (en) 2020-03-19
JP7366002B2 (ja) 2023-10-20
JP7642707B2 (ja) 2025-03-10
JP2020530837A (ja) 2020-10-29
RU2020108634A3 (enExample) 2021-11-30
US20250017890A1 (en) 2025-01-16
KR20200045489A (ko) 2020-05-04
KR102643275B1 (ko) 2024-03-04
CN111094238B (zh) 2023-06-09
EP3661911A1 (en) 2020-06-10
SA520411187B1 (ar) 2024-10-17

Similar Documents

Publication Publication Date Title
AU2018312328B2 (en) Carbamoyl phenylalaninol analogs and uses thereof
US11780805B2 (en) Carbamoyl phenylalaninol compounds and uses thereof
US20230183172A1 (en) Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
WO2016199906A1 (ja) スルホンアミド誘導体またはその薬学的に許容される酸付加塩
EP3943495A1 (en) Small molecule modulators of il-17
TW200845995A (en) Diaminopyrimidines
KR101455484B1 (ko) 항말라리아제로서 피페라진
HK40003964A (en) Carbamoyl phenylalaninol compounds and uses therof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)